Fc-silenced antibodies to remove effector functions

Therapeutic antibodies with mutated Fc regions demonstrate reduced Fc-effector functions (such as cytokine release) in vivo. This is essential for therapeutic applications where activation of the host’s immune system would have negative effects, such as when an antibody is used to neutralize a binding interaction.

Many mutations exist which silence the Fc domain, but all previously described version have some background activity and intellectual property limitations. 

evitria holds a licensing partnership to offer antibodies with truly silent Fc domains, using mAbsolve’s STR technology. These antibodies display zero activity above background noise.

0 >

Antibody production runs

0 < day

Lead time

0 > %

Projects completed on time

evitria uses mAbsolve’s STR technology

STR is a novel combination of three mutations in the CH2 domain of the Fc. STR-modified antibodies show no binding or activity above background noise across the Fc gamma receptors, far surpassing all previously described modifications.

STR is readily available to license, and evitria is partnered with mAbsolve to offer truly silent Fc domains for preclinical use.

More about STR from mAbsolve.

Benefits of producing STR-modified antibodies with evitria

Benefits of producing STR-modified antibodies with evitria

Sourcing STR-silenced antibodies through evitria enables our clients to benefit by gaining:  

  • Access to a research license for their related experiments without an ongoing fee
  • Technical support from the mAbsolve team and STR inventors to assist in their experimental design and result interpretation
  • Verification they have freedom-to-operate within mAbsolve’s patent and exclusively licenced portfolio
  • An insight into future licence terms early on in their development work, to provide a clear commercialization pathway
  • Our capabilities in recombinant antibody production enable us to meet the highest quality standards at fast delivery times.

From sequence to antibody in 5 weeks

project start - how we work at evitria

Project start

0-1 business days

pilot study (from electronic sequence to quantified pilot supernatant)

Pilot study

(from electronic sequence to quantified pilot supernatant)

15-20 business days

larger-scale expression - how we work at evitria

Larger-scale expression

5-10 business days

purification - how we work at evitria

Purification

2-3 business days

final analytics - how we work at evitria

Final analytics

2-3 business days

shipment - how we work at evitria

Shipment

1-2 business days

How to order with evitria

You tell us what you need and when

Optional: We discuss your project and how we might be able to assist in a personal conversation

You receive our proposal within one working day

You review and approve our proposal

Your project begins within one working day

In vitro antibody production services

Where reliability counts

For your projects in Medicine or Research, both quality and time are of essence. As an antibody expression service provider, we help our customers out with a fast delivery of high-qualitative antibodies produced with recombinant technology.

At evitria, we provide not only Fc-silenced antibodies, but also

In addition to this, our expert team conducts a careful sequence and project review, so that we can provide you with high-quality antibodies for your project – from sequence to antibody in 5 weeks.

After your approval, we begin with your project within one business day!

February 29, 2024 duration: 9 min

An Introduction to Recombinant Antibodies: 7 Key Insights

From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
November 21, 2023 duration: 6 min

Afucosylated recombinant antibodies

Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
September 30, 2021 duration: 6 min

Antibody-Dependent Cellular Cytotoxicity (ADCC) – definition, mechanism & application

Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
February 27, 2023 duration: 8 min

Recombinant Antibody Production: Complete Guide

Recombinant antibody production is vital in drug development as well as for therapeutic and research purposes. In this article, we will discuss methods and benefits of recombinant antibody production.

Christian Eberle

Christian Eberle

Former CEO of evitria AG (2020-2023)
December 13, 2022 duration: 6 min

Recombinant DNA technology – Steps, Methods & Examples

Recombinant technology is used in very different fields – from agriculture to medical research and disease therapy. Here’s everything you need to know on the technology.

Christian Eberle

Christian Eberle

Former CEO of evitria AG (2020-2023)
March 10, 2022 duration: 4 min

Fc Silenced Antibody – Therapeutic antibodies with reduced side effect profile

One of the most exciting recent developments in the sector is the engineering of antibodies’ fragment crystallizable (Fc region). Fc engineering entails the optimization of recombinant monoclonal antibodies, anticancer bispecific antibodies​ and Fc fusion proteins by means of modifications at specific residues to enhance performance in their intended applications​. Read more!

Desmond Schofield

Desmond Schofield

Director of Business Development at evitria
Get in Touch

    Subscribe to the evitria newsletter and stay up to date